AngioDynamics' CEO Eamonn Hobbs Granted Honorary Fellowship by Society of Interventional Radiology.QUEENSBURY, N.Y. -- AngioDynamics, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ANGO ANGO Algemene Nederlandse Gehandicapten Organisatie (Dutch: Equal Opportunities for Persons with Disabilities) ) today announced that Eamonn Hobbs, president and chief executive officer, was granted an Honorary Fellowship from the Society of Interventional Radiology interventional radiology Imaging A subspecialty of radiology that provides Diagnostic information–eg, CT-guided 'skinny' needle biopsies and dye injection for analysis of various lumina and tracts–eg, arteriography, cholangiography, antegrade (SIR) at an induction ceremony on Saturday evening, April 3, 2005. The fellowship was granted in conjunction with the annual meeting of SIR being held in New Orleans March 31 through April 5, 2005. In its 32 years since inception in 1973, only 10 individuals have ever been granted Honorary Fellowships. Janette D. Durham, M.D., M.B.A. and president of SIR wrote in her nomination letter, "Eamonn has been dedicated to research and the development of interventional radiology products since his company was founded... Eamonn's commitment to the development of innovative devices for angiography angiography or arteriography X-ray examination of arteries and veins with a contrast medium to differentiate them from surrounding organs. The contrast medium is introduced through a catheter to show the blood vessels and the structures they supply, including , thrombolytic thrombolytic /throm·bo·lyt·ic/ (throm?bo-lit´ik) dissolving or splitting up a thrombus, or an agent that so acts. thrombolytic 1. dissolving or splitting up a thrombus. 2. an agent that dissolves or splits up a thrombus. delivery, and venous disease has furthered the innovative treatment and patient care options for the specialty of IR." "I am truly honored to be granted this recognition," said Eamonn Hobbs. "The new innovative minimally invasive procedures developed by interventional radiologists have been vital to improving patients' lives. AngioDynamics has had the good fortune to be able to support these new procedures by working in close collaboration with interventional radiologists to develop new medical devices that allow physicians to more easily treat their patients. We will continue to work with SIR members on new ideas for the treatment of peripheral vascular diseases." The Society of Interventional Radiology is a non-profit, national scientific organization of more than 4000 physicians and allied health professionals committed to improving health and the quality of life through the practice of vascular and interventional radiology. The Society promotes education, research and communication, while providing leadership in the development of healthcare policy. About AngioDynamics AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of products used by interventional radiologists and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans", "believes", "seeks", "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the outcome of the Diomed patent litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Form 10-Q Form 10-Q See 10-Q. for the quarter ended November 27, 2004, and its Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended May 29, 2004, may affect the actual results achieved by the Company. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion